Lung abscess medical therapy

Jump to navigation Jump to search

Abscess Main Page

Lung abscess Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Lung abscess from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lung abscess medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lung abscess medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lung abscess medical therapy

CDC on Lung abscess medical therapy

Lung abscess medical therapy in the news

Blogs on Lung abscess medical therapy

Directions to Hospitals Treating Lung abscess

Risk calculators and risk factors for Lung abscess medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Medical Therapy

  • Empiric treatment should be commenced after culture samples are obtained.
  • The choice of empiric antibiotics should be determined on the basis of the possible risk of multi-drug resistant causative bacteria, and culture results.

The following table summarizes the treatment for Lung abscess

Pathogens Age group specific therapy
Adult
Empiric Anaerobes and microaerophilic streptococci
  •         Ampicillin +sulbactum  3g IV q6h[1]

(or)

  •        Imipenem+cilastin  500 mg IV q6h

(or)

  •         Meropenem    1-2 g IV q8h
Alternnative[2] Clindamycin  IV 600 mg q8h

150 to 300 mg orally four times daily

Pathogen directed MSSA Nafcillin 2 g IV q4h OR Oxacillin 2 g IV q4h OR Cefazolin 2 g IV q8h
MRSA Linezolid 600 mg q12h IV/PO ± Rifampin 300 mg po/IV bid sue=9725 |pages=1557–68 |year=2010 |pmid=20206987 |pmc=3511788 |doi=10.1016/S0140-6736(09)61999-1 |url=}}</ref>
Actinomyces Intravenous penicillin G (10 to 20 million units daily in divided doses every four to six hours) for 4 to 6 weeks, 
Nocardia .spp TMP-SMX 15 mg/kg IV of the trimethoprim component per day in three or four divided doses 

PLUS

Amikacin 7.5 mg/kg IV every 12 hours 

Fungi Amphotericin B  3-5mg/kg/day/IV
Parasite Albendazole is dosed 10 to 15 mg/kg per day in two divided doses; the usual dose for adults is 400 mg twice daily.

one to three months may be a ppropriate, depending clinical factors; up to six months may be required.

  • Clinical improvement is reflected in the subsidence of fever (within the first 3-4 days) and complete defervescence within 7-10 days.Persistent fever can be explained by treatment failure due to uncommon pathogens (multidrug resistant common bacteria, mycobacteria, fungi)or by the presence of an alternative diagnosis (e.g. endobronchial obstruction, vasculitis) that requires further diagnostic workup (e.g. bronchoscopy, transdermal or surgical lung biopsy).[3]
  • The duration of treatment with antibiotics is not well defined, according to many experts, the optimal duration of antimicrobial therapy is 3-6 weeks, whereas others take the timing of radiological response into consideration. [3]
  • In that case, the length of antibiotic treatment depends on complete radiological resolution or stabilization to a small residual lesion.
  • Treatment interval may then be prolonged to several months (more than 2),6 especially when the initial lesion is of large size (maximum diameter more than 6cm).

Reference

  1. Germaud P, Poirier J, Jacqueme P, Guerin JC, Benard Y, Boutin C, Brambilla C, Escamilla R, Zuck P (1993). "[Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess. Apropos of 57 cases]". Rev Pneumol Clin (in French). 49 (3): 137–41. PMID 8296141.
  2. Levison ME, Mangura CT, Lorber B, Abrutyn E, Pesanti EL, Levy RS, MacGregor RR, Schwartz AR (1983). "Clindamycin compared with penicillin for the treatment of anaerobic lung abscess". Ann. Intern. Med. 98 (4): 466–71. PMID 6838068.
  3. 3.0 3.1 Takayanagi N, Kagiyama N, Ishiguro T, Tokunaga D, Sugita Y (2010). "Etiology and outcome of community-acquired lung abscess". Respiration. 80 (2): 98–105. doi:10.1159/000312404. PMID 20389050.

Template:WikiDoc Sources